Cymabay Therapeutics Story Overview

CBAY -- USA Stock  

USD 10.18  0.19  1.90%

Macroaxis does not monitor all media channels or aggregates social signals for Cymabay Therapeutics. But even though we do not provide professional-grade financial sentiment analysis on Cymabay Therapeutics, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Cymabay Therapeutics. Check also Cymabay Therapeutics Hype Analysis, Cymabay Therapeutics Correlation and Cymabay Therapeutics Performance.
Trading Sheet Reviewing the Levels for Cymabay Therapeutics, Inc.
Cymabay Therapeutics, Inc. presently has an EV or Enterprise Value of 291551. The EV helps show how the market assigns value to a company as a whole.

Read More...   

Story Momentum

This media report from www.concordregister.com distributed on December 7, 2017 was a factor to the next trading day price appreciation.The overall trading delta against the next closing price was 0.73% . The overall trading delta when the story was published against the current closing price is 23.22% .

Similar stores for Cymabay Therapeutics

Malibu Boats INC Stake Maintained by Eam Investors Llcnews
The Cardinal Weekly Full coverage
over a week ago at http://reagentsglobalmarket.com 
Latest Movement CymaBay Therapeutics
news
Reagents Global MarketBank of New York Mellon Corp Has 3.25 Million Position in CymaBay Therapeutics Inc PressOracleFull coverage
over a week ago at http://www.whatsonthorold.com 
Sage Therapeutics INC Shareholder Baker Bros Advisors LP Has Trimmed Its Stake by 5.23 Million
news
Thorold NewsFull coverage
over two weeks ago at http://www.thecoinguild.com 
Market News Investors Keen on CymaBay Therapeutics Inc. as it Makes Waves With Moves
news
The Coin GuildFull coverage
over three weeks ago at http://kreviewer.com 
Westpac Banking Increases Position in Washington Real Estate Invt Rock Springs Capital Management LP Has ...
news
K ReviewerFull coverage
over a month ago at http://thewellesleysnews.com 
Influential Analyst Rating Changes CymaBay Therapeutics, Inc. , Harris Corporation
news
Analyst JournalFull coverage
over a month ago at http://reagentsglobalmarket.com 
Stock to Track CymaBay Therapeutics
news
Reagents Global MarketReviewing CymaBay Therapeutics and Prestige Consumer Healthcare Fairfield CurrentFull coverage
over a month ago at http://www.fairfieldcurrent.com 
Head-To-Head Contrast CymaBay Therapeutics versus Myokardia
news
Fairfield CurrentFull coverage
over a month ago at http://kentwoodpost.com 
What Can the Quant Signals Tell us About CymaBay Therapeutics, Inc. With an EBITDA of ...
news
Kentwood PostFull coverage
over a month ago at http://thewellesleysnews.com 
Investment Research Analysts Opinion EnerSys , CymaBay Therapeutics, Inc.
news
Analyst JournalFull coverage
over a month ago at http://nysewired.com 
Analysts Call Attention CymaBay Therapeutics
wired  News
NYSE WIRED Full coverage
over three months ago at http://thewellesleysnews.com 
CymaBay Therapeutics, Inc. Consensus EPS Outlook
news
Analyst JournalFull coverage
over three months ago at http://bzweekly.com 
Abingworth Llp Has Trimmed Cymabay Stake by 3.56 Million as Stock Price Rose Schwab Charles Cp New ...
news
BZ WeeklyFull coverage

Net Income

Net Income Comparative Analysis

  Net Income 
      Cymabay Therapeutics Comparables 
Cymabay Therapeutics is currently under evaluation in net income category among related companies. Net income is the profit of a company for the reporting period which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most watched numbers by money managers as well as individual investors.

Peers

Cymabay Therapeutics Related Equities

NK  9.90 %   
0%
19.0%
DMPI  7.43 %   
0%
14.0%
CO  3.90 %   
0%
7.0%
DOVA  1.13 %   
0%
2.0%
ECYT  0.98 %   
0%
1.0%
DRNA  0.61 %   
1.0%
0%
DVAX  1.8 %   
3.0%
0%
DNLI  5.53 %   
10.0%
0%
EARS  50.72 %   
100.0%
0%
Check also Cymabay Therapeutics Hype Analysis, Cymabay Therapeutics Correlation and Cymabay Therapeutics Performance. Please also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Search macroaxis.com